ATNM Q1 2026 Earnings NarrowerthanExpected Loss Highlights Controlled Spending Amid Clinical Progress RY Q1 2026 Earnings EPS Beats Estimates Amid Mixed Market Signals CF Q1 2026 Earnings Strong EPS Beat Offsets Flat Revenue Outlook DRMA Q1 2026 Earnings NarrowerthanExpected Loss Marks Progress for ClinicalStage Biotech DOX Q1 2026 Earnings EPS Slightly Misses Estimates Stock Edges Lower Soleno Therapeutics Q1 2026 Earnings EPS Misses Estimates by 1494 Stock Holds Steady